Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity

Dengue virus infections are still increasing at an alarming rate in tropical and subtropical countries, underlying the need for a dengue vaccine. Although it is relatively easy to generate Ab responses to dengue virus, low avidity or low concentrations of Ab may enhance infection of FcR-bearing cells with clinical impact, posing a challenge to vaccine production. In this article, we report the characterization of a mAb, 2H12, which is cross-reactive to all four serotypes in the dengue virus group. Crystal structures of 2H12-Fab in complex with domain III of the envelope protein from three dengue serotypes have been determined. 2H12 binds to the highly conserved AB loop of domain III of the envelope protein that is poorly accessible in the mature virion. 2H12 neutralization varied between dengue serotypes and strains; in particular, dengue serotype 2 was not neutralized. Because the 2H12-binding epitope was conserved, this variation in neutralization highlights differences between dengue serotypes and suggests that significant conformational changes in the virus must take place for Ab binding. Surprisingly, 2H12 facilitated little or no enhancement of infection. These data provide a structural basis for understanding Ab neutralization and enhancement of infection, which is crucial for the development of future dengue vaccines.

[1]  C. Nelson,et al.  The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 , 2010, PLoS pathogens.

[2]  M. Accavitti-Loper,et al.  Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.

[3]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[4]  S. Halstead,et al.  Dengue Viruses and Mononuclear Phagocytes , 2003 .

[5]  S. Halstead,et al.  Antibody-enhanced dengue virus infection in primate leukocytes , 1977, Nature.

[6]  Graeme Winter,et al.  xia2: an expert system for macromolecular crystallography data reduction , 2010 .

[7]  S. Harrison,et al.  The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.

[8]  G. Nybakken,et al.  West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody , 2006, Proceedings of the National Academy of Sciences.

[9]  C. Hayes,et al.  Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. , 1998, The American journal of tropical medicine and hygiene.

[10]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[11]  Ya-jun Guo,et al.  A Broadly Flavivirus Cross-Neutralizing Monoclonal Antibody that Recognizes a Novel Epitope within the Fusion Loop of E Protein , 2011, PloS one.

[12]  J. Blok Genetic relationships of the dengue virus serotypes. , 1985, The Journal of general virology.

[13]  L. James,et al.  Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21) , 2010, Proceedings of the National Academy of Sciences.

[14]  S. Green,et al.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever , 2006, Current opinion in infectious diseases.

[15]  C. Anderson,et al.  Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. , 1985, Journal of immunology.

[16]  R. Warren,et al.  Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. , 1995, Vaccine.

[17]  M. St. Claire,et al.  Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention , 2007, Proceedings of the National Academy of Sciences.

[18]  M. Diamond,et al.  Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.

[19]  K. Nilsson,et al.  Establishment and characterization of a human histiocytic lymphoma cell line (U‐937) , 1976, International journal of cancer.

[20]  Alfonso Gúzman,et al.  Update on the global spread of dengue. , 2010, International journal of antimicrobial agents.

[21]  David I. Stuart,et al.  A procedure for setting up high-throughput nanolitre crystallization experiments. II. Crystallization results , 2003 .

[22]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[23]  Soila Sukupolvi-Petty,et al.  On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. , 2009, The Journal of general virology.

[24]  Gregory D. Gromowski,et al.  Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. , 2010, Virology.

[25]  C. Parrish,et al.  Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. , 1994, Virology.

[26]  Y. Modis,et al.  A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Murphy,et al.  Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. , 2001, The American journal of tropical medicine and hygiene.

[28]  G. Chang,et al.  Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes , 2004, Journal of Virology.

[29]  Gregory D. Gromowski,et al.  Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. , 2009, Virology.

[30]  Gregory D. Gromowski,et al.  Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes , 2007, Journal of Virology.

[31]  Cameron P. Simmons,et al.  An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection , 2010, Journal of Virology.

[32]  J. Smit,et al.  Immature Dengue Virus: A Veiled Pathogen? , 2010, PLoS pathogens.

[33]  D. Gubler The global emergence/resurgence of arboviral diseases as public health problems. , 2002, Archives of medical research.

[34]  Soila Sukupolvi-Petty,et al.  Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3 , 2010, Journal of Virology.

[35]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[36]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[37]  Gregory D. Gromowski,et al.  Short Communication Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III , 2010 .

[38]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[39]  Richard J Kuhn,et al.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins , 2008, Nature Structural &Molecular Biology.

[40]  Gregory D. Gromowski,et al.  Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus , 2008, Journal of Virology.

[41]  R. Rico-Hesse,et al.  Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2 , 2010, Journal of Virology.

[42]  M. Guzmán,et al.  Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. , 2008, Virus research.

[43]  G. Siuzdak,et al.  Antiviral agent blocks breathing of the common cold virus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Chin,et al.  The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. , 2007, Microbes and infection.

[45]  J. Esko,et al.  Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate , 1997, Nature Medicine.

[46]  Ralph S. Baric,et al.  Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses , 2010, PLoS pathogens.

[47]  J. Roehrig,et al.  Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells , 2001, Journal of Virology.

[48]  Eugene Krissinel,et al.  The CCP4 molecular-graphics project. , 2002, Acta crystallographica. Section D, Biological crystallography.

[49]  G. Chang,et al.  Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens , 2009, PloS one.

[50]  C. Anderson,et al.  Human monocytes and U937 cells bear two distinct Fc receptors for IgG. , 1986, Journal of immunology.

[51]  C. Lai,et al.  Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. , 1996, Virology.

[52]  J. Roehrig,et al.  Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. , 1998, Virology.

[53]  SB Halstead,et al.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.

[54]  G. Chang,et al.  Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II , 2008, Journal of Virology.

[55]  K. Stiasny,et al.  Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites , 2006, Journal of Virology.

[56]  T. Oliphant,et al.  Structural basis of West Nile virus neutralization by a therapeutic antibody , 2005, Nature.

[57]  Wen Chang,et al.  An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells , 2004, Journal of Virology.

[58]  Lester G. Carter,et al.  A procedure for setting up high‐throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization , 2005, Acta crystallographica. Section D, Biological crystallography.

[59]  S. Halstead In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. , 1979, The Journal of infectious diseases.

[60]  A. Sabin Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[61]  M. Guzmán,et al.  Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins , 2008, Archives of Virology.

[62]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[63]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[64]  H. Bedouelle,et al.  Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. , 2001, The Journal of general virology.

[65]  Martyn D Winn,et al.  Macromolecular TLS refinement in REFMAC at moderate resolutions. , 2003, Methods in enzymology.

[66]  T. Osawa,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010 .

[67]  G. Chinea,et al.  Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. , 2008, Virus research.

[68]  D. Burton,et al.  Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. , 2003, Advances in experimental medicine and biology.

[69]  John E. Johnson,et al.  Evidence of Viral Capsid Dynamics Using Limited Proteolysis and Mass Spectrometry* , 1998, The Journal of Biological Chemistry.

[70]  Hugues Bedouelle,et al.  Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. , 2012, Structure.

[71]  K. Stiasny,et al.  Immunodominance and Functional Activities of Antibody Responses to Inactivated West Nile Virus and Recombinant Subunit Vaccines in Mice , 2010, Journal of Virology.

[72]  S. Yoksan,et al.  The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[73]  Gregory D. Gromowski,et al.  Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. , 2007, Virology.

[74]  M. Frohman,et al.  Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Y. Modis,et al.  Variable Surface Epitopes in the Crystal Structure of Dengue Virus Type 3 Envelope Glycoprotein , 2005, Journal of Virology.

[76]  M. Aye,et al.  Risk factors in dengue shock syndrome. , 1997, The American journal of tropical medicine and hygiene.